Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.

Marsden MD, Wu X, Navab SM, Loy BA, Schrier AJ, DeChristopher BA, Shimizu AJ, Hardman CT, Ho S, Ramirez CM, Wender PA, Zack JA.

Virology. 2018 Jul;520:83-93. doi: 10.1016/j.virol.2018.05.006. Epub 2018 May 26.

2.

Correction: Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS.

Zhen A, Peterson CW, Carrillo MA, Reddy SS, Youn CS, Lam BB, Chang NY, Martin HA, Rick JW, Kim J, Neel NC, Rezek VK, Kamata M, Chen ISY, Zack JA, Kiem HP, Kitchen SG.

PLoS Pathog. 2018 Mar 12;14(3):e1006891. doi: 10.1371/journal.ppat.1006891. eCollection 2018 Mar.

3.

Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS.

Zhen A, Peterson CW, Carrillo MA, Reddy SS, Youn CS, Lam BB, Chang NY, Martin HA, Rick JW, Kim J, Neel NC, Rezek VK, Kamata M, Chen ISY, Zack JA, Kiem HP, Kitchen SG.

PLoS Pathog. 2017 Dec 28;13(12):e1006753. doi: 10.1371/journal.ppat.1006753. eCollection 2017 Dec. Erratum in: PLoS Pathog. 2018 Mar 12;14 (3):e1006891.

4.

Differentiation of RPE cells from integration-free iPS cells and their cell biological characterization.

Hazim RA, Karumbayaram S, Jiang M, Dimashkie A, Lopes VS, Li D, Burgess BL, Vijayaraj P, Alva-Ornelas JA, Zack JA, Kohn DB, Gomperts BN, Pyle AD, Lowry WE, Williams DS.

Stem Cell Res Ther. 2017 Oct 2;8(1):217. doi: 10.1186/s13287-017-0652-9.

5.

In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.

Marsden MD, Loy BA, Wu X, Ramirez CM, Schrier AJ, Murray D, Shimizu A, Ryckbosch SM, Near KE, Chun TW, Wender PA, Zack JA.

PLoS Pathog. 2017 Sep 21;13(9):e1006575. doi: 10.1371/journal.ppat.1006575. eCollection 2017 Sep.

6.

New approaches for the enhancement of chimeric antigen receptors for the treatment of HIV.

Carrillo MA, Zhen A, Zack JA, Kitchen SG.

Transl Res. 2017 Sep;187:83-92. doi: 10.1016/j.trsl.2017.07.002. Epub 2017 Jul 14. Review.

PMID:
28755872
7.

Humanized Mouse Models for Human Immunodeficiency Virus Infection.

Marsden MD, Zack JA.

Annu Rev Virol. 2017 Sep 29;4(1):393-412. doi: 10.1146/annurev-virology-101416-041703. Epub 2017 Jul 26. Review.

PMID:
28746819
8.

Engineering HIV-Specific Immunity with Chimeric Antigen Receptors.

Kitchen SG, Zack JA.

AIDS Patient Care STDS. 2016 Dec;30(12):556-561.

9.

Propagating Humanized BLT Mice for the Study of Human Immunology and Immunotherapy.

Smith DJ, Lin LJ, Moon H, Pham AT, Wang X, Liu S, Ji S, Rezek V, Shimizu S, Ruiz M, Lam J, Janzen DM, Memarzadeh S, Kohn DB, Zack JA, Kitchen SG, An DS, Yang L.

Stem Cells Dev. 2016 Dec 15;25(24):1863-1873. Epub 2016 Oct 18.

10.

HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies.

Ali A, Kitchen SG, Chen ISY, Ng HL, Zack JA, Yang OO.

J Virol. 2016 Jul 11;90(15):6999-7006. doi: 10.1128/JVI.00805-16. Print 2016 Aug 1.

11.

Medial HOXA genes demarcate haematopoietic stem cell fate during human development.

Dou DR, Calvanese V, Sierra MI, Nguyen AT, Minasian A, Saarikoski P, Sasidharan R, Ramirez CM, Zack JA, Crooks GM, Galic Z, Mikkola HK.

Nat Cell Biol. 2016 Jun;18(6):595-606. doi: 10.1038/ncb3354. Epub 2016 May 16.

12.

A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.

Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, Karumbayaram S, Kumagai-Cresse C, Wang D, Zack JA, Kohn DB, Nakano A, Nelson SF, Miceli MC, Spencer MJ, Pyle AD.

Cell Stem Cell. 2016 Apr 7;18(4):533-40. doi: 10.1016/j.stem.2016.01.021. Epub 2016 Feb 11.

13.

Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.

Akkina R, Allam A, Balazs AB, Blankson JN, Burnett JC, Casares S, Garcia JV, Hasenkrug KJ, Kashanchi F, Kitchen SG, Klein F, Kumar P, Luster AD, Poluektova LY, Rao M, Sanders-Beer BE, Shultz LD, Zack JA.

AIDS Res Hum Retroviruses. 2016 Feb;32(2):109-19. doi: 10.1089/AID.2015.0258.

14.

Disruption of Type I Interferon Induction by HIV Infection of T Cells.

Sanchez DJ, Miranda D Jr, Marsden MD, Dizon TM, Bontemps JR, Davila SJ, Del Mundo LE, Ha T, Senaati A, Zack JA, Cheng G.

PLoS One. 2015 Sep 16;10(9):e0137951. doi: 10.1371/journal.pone.0137951. eCollection 2015.

15.

Corrigendum: Cocaine exposure impairs multilineage hematopoiesis of human hematopoietic progenitor cells mediated by the sigma-1 receptor.

Nixon CC, Schwartz BH, Dixit D, Zack JA, Vatakis DN.

Sci Rep. 2015 Jul 13;5:9798. doi: 10.1038/srep09798. No abstract available.

16.

Cocaine-mediated impact on HIV infection in humanized BLT mice.

Kim SG, Lowe EL, Dixit D, Youn CS, Kim IJ, Jung JB, Rovner R, Zack JA, Vatakis DN.

Sci Rep. 2015 Jun 18;5:10010. doi: 10.1038/srep10010.

17.

HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells.

Zhen A, Kamata M, Rezek V, Rick J, Levin B, Kasparian S, Chen IS, Yang OO, Zack JA, Kitchen SG.

Mol Ther. 2015 Aug;23(8):1358-1367. doi: 10.1038/mt.2015.102. Epub 2015 Jun 8.

18.

Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging.

McCracken MN, Vatakis DN, Dixit D, McLaughlin J, Zack JA, Witte ON.

J Clin Invest. 2015 May;125(5):1815-26. doi: 10.1172/JCI77326. Epub 2015 Mar 30.

19.

Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs.

Menon T, Firth AL, Scripture-Adams DD, Galic Z, Qualls SJ, Gilmore WB, Ke E, Singer O, Anderson LS, Bornzin AR, Alexander IE, Zack JA, Verma IM.

Cell Stem Cell. 2015 Apr 2;16(4):367-72. doi: 10.1016/j.stem.2015.02.005. Epub 2015 Mar 12.

20.

Cocaine exposure impairs multilineage hematopoiesis of human hematopoietic progenitor cells mediated by the sigma-1 receptor [corrected].

Nixon CC, Schwartz BH, Dixit D, Zack JA, Vatakis DN.

Sci Rep. 2015 Mar 2;5:8670. doi: 10.1038/srep08670. Erratum in: Sci Rep. 2015;5:9798.

21.

RNAi-Mediated CCR5 Knockdown Provides HIV-1 Resistance to Memory T Cells in Humanized BLT Mice.

Shimizu S, Ringpis GE, Marsden MD, Cortado RV, Wilhalme HM, Elashoff D, Zack JA, Chen IS, An DS.

Mol Ther Nucleic Acids. 2015 Feb 17;4:e227. doi: 10.1038/mtna.2015.3.

22.

Studies of retroviral infection in humanized mice.

Marsden MD, Zack JA.

Virology. 2015 May;479-480:297-309. doi: 10.1016/j.virol.2015.01.017. Epub 2015 Feb 11. Review.

23.

Double trouble: HIV latency and CTL escape.

Marsden MD, Zack JA.

Cell Host Microbe. 2015 Feb 11;17(2):141-2. doi: 10.1016/j.chom.2015.01.008.

24.

Experimental Approaches for Eliminating Latent HIV.

Marsden MD, Zack JA.

For Immunopathol Dis Therap. 2015;6(1-2):91-99.

25.

Neutralizing the HIV reservoir.

Marsden MD, Zack JA.

Cell. 2014 Aug 28;158(5):971-972. doi: 10.1016/j.cell.2014.08.010.

26.

Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery.

Buehler DC, Marsden MD, Shen S, Toso DB, Wu X, Loo JA, Zhou ZH, Kickhoefer VA, Wender PA, Zack JA, Rome LH.

ACS Nano. 2014 Aug 26;8(8):7723-32. doi: 10.1021/nn5002694. Epub 2014 Jul 31.

27.

CD4 ligation on human blood monocytes triggers macrophage differentiation and enhances HIV infection.

Zhen A, Krutzik SR, Levin BR, Kasparian S, Zack JA, Kitchen SG.

J Virol. 2014 Sep 1;88(17):9934-46. doi: 10.1128/JVI.00616-14. Epub 2014 Jun 18.

28.

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2457-65. doi: 10.1158/1078-0432.CCR-13-3017. Epub 2014 Mar 14.

29.

Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status.

Awe JP, Lee PC, Ramathal C, Vega-Crespo A, Durruthy-Durruthy J, Cooper A, Karumbayaram S, Lowry WE, Clark AT, Zack JA, Sebastiano V, Kohn DB, Pyle AD, Martin MG, Lipshutz GS, Phelps PE, Pera RA, Byrne JA.

Stem Cell Res Ther. 2013 Jul 26;4(4):87. doi: 10.1186/scrt246.

30.

HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice.

Nixon CC, Vatakis DN, Reichelderfer SN, Dixit D, Kim SG, Uittenbogaart CH, Zack JA.

Blood. 2013 Sep 26;122(13):2195-204. doi: 10.1182/blood-2013-04-496950. Epub 2013 Jul 25.

31.

Cocaine exposure enhances permissiveness of quiescent T cells to HIV infection.

Kim SG, Jung JB, Dixit D, Rovner R Jr, Zack JA, Baldwin GC, Vatakis DN.

J Leukoc Biol. 2013 Oct;94(4):835-43. doi: 10.1189/jlb.1112566. Epub 2013 Jul 1.

32.

Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo.

Beans EJ, Fournogerakis D, Gauntlett C, Heumann LV, Kramer R, Marsden MD, Murray D, Chun TW, Zack JA, Wender PA.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11698-703. doi: 10.1073/pnas.1302634110. Epub 2013 Jun 28.

33.

HIV/AIDS eradication.

Marsden MD, Zack JA.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4003-10. doi: 10.1016/j.bmcl.2013.05.032. Epub 2013 May 18. Review.

34.

HIV restriction in quiescent CD4⁺ T cells.

Zack JA, Kim SG, Vatakis DN.

Retrovirology. 2013 Apr 4;10:37. doi: 10.1186/1742-4690-10-37. Review.

35.

Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression.

Vatakis DN, Arumugam B, Kim SG, Bristol G, Yang O, Zack JA.

Mol Ther. 2013 May;21(5):1055-63. doi: 10.1038/mt.2013.28. Epub 2013 Mar 12.

36.

Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol.

Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK, Pernet O, Guo H, Nusbaum R, Zack JA, Freiberg AN, Su L, Lee B, Cheng G.

Immunity. 2013 Jan 24;38(1):92-105. doi: 10.1016/j.immuni.2012.11.005. Epub 2012 Dec 27.

37.

Using the BLT humanized mouse as a stem cell based gene therapy tumor model.

Vatakis DN, Bristol GC, Kim SG, Levin B, Liu W, Radu CG, Kitchen SG, Zack JA.

J Vis Exp. 2012 Dec 18;(70):e4181. doi: 10.3791/4181.

38.

From skin biopsy to neurons through a pluripotent intermediate under Good Manufacturing Practice protocols.

Karumbayaram S, Lee P, Azghadi SF, Cooper AR, Patterson M, Kohn DB, Pyle A, Clark A, Byrne J, Zack JA, Plath K, Lowry WE.

Stem Cells Transl Med. 2012 Jan;1(1):36-43. doi: 10.5966/sctm.2011-0001. Epub 2011 Dec 7.

39.

Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro.

DeChristopher BA, Loy BA, Marsden MD, Schrier AJ, Zack JA, Wender PA.

Nat Chem. 2012 Sep;4(9):705-10. doi: 10.1038/nchem.1395. Epub 2012 Jul 15.

40.

Virological evidence supporting the use of raltegravir in HIV post-exposure prophylaxis regimens.

Marsden MD, Krogstad PA, Zack JA.

Antivir Ther. 2012;17(7):1375-9. doi: 10.3851/IMP2255. Epub 2012 Jul 20.

PMID:
22820096
41.

In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells.

Kitchen SG, Levin BR, Bristol G, Rezek V, Kim S, Aguilera-Sandoval C, Balamurugan A, Yang OO, Zack JA.

PLoS Pathog. 2012;8(4):e1002649. doi: 10.1371/journal.ppat.1002649. Epub 2012 Apr 12.

42.

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A, Radu CG, Galic Z, Zack JA.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):E1408-16. doi: 10.1073/pnas.1115050108. Epub 2011 Nov 28.

43.

Genome-wide binding map of the HIV-1 Tat protein to the human genome.

Marban C, Su T, Ferrari R, Li B, Vatakis D, Pellegrini M, Zack JA, Rohr O, Kurdistani SK.

PLoS One. 2011;6(11):e26894. doi: 10.1371/journal.pone.0026894. Epub 2011 Nov 4.

44.

HIV latency in the humanized BLT mouse.

Marsden MD, Kovochich M, Suree N, Shimizu S, Mehta R, Cortado R, Bristol G, An DS, Zack JA.

J Virol. 2012 Jan;86(1):339-47. doi: 10.1128/JVI.06366-11. Epub 2011 Nov 9.

45.

HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genes.

Marsden MD, Burke BP, Zack JA.

Virology. 2011 Sep 1;417(2):394-9. doi: 10.1016/j.virol.2011.06.024. Epub 2011 Jul 20.

46.

Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt.

Mitsuyasu RT, Zack JA, Macpherson JL, Symonds GP.

Stem Cells Int. 2011;2011:393698. doi: 10.4061/2011/393698. Epub 2011 Jun 13.

47.

Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.

Marsden MD, Avancena P, Kitchen CM, Hubbard T, Zack JA.

Antimicrob Agents Chemother. 2011 Aug;55(8):3696-702. doi: 10.1128/AAC.00566-11. Epub 2011 May 31.

48.

Activation of latent HIV using drug-loaded nanoparticles.

Kovochich M, Marsden MD, Zack JA.

PLoS One. 2011 Apr 5;6(4):e18270. doi: 10.1371/journal.pone.0018270.

49.
50.

Stem cell-based approaches to treating HIV infection.

Kitchen SG, Zack JA.

Curr Opin HIV AIDS. 2011 Jan;6(1):68-73. doi: 10.1097/COH.0b013e3283412370. Review.

Supplemental Content

Support Center